Members - CEO Roundtable on Cancer

Member Since 2018

AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
Member Since 2020

Randy Trice

Chief Executive Officer

Randy Trice serves as the CEO of Alphanumeric, where he is responsible for setting the corporate direction, driving performance, and ensuring the corporate vision is carried out. His strategic leadership has enabled the organization to reach its maximum potential, resulting in growth, operational effectiveness, and market influence. As a leader, he fosters a culture of performance, ownership, and success, empowering his team to deliver exceptional results. Randy’s passion for improving market share, revenue, and EBITDA, combined with his strategic vision and ability to execute with urgency, has enabled him to lead Alphanumeric successfully through periods of growth and challenge. Under his leadership, Alphanumeric has experienced significant increases in both market share and profitability, thanks in part to key relationships he has forged with other businesses and organizations. Randy currently serves as an active member of the CEO Roundtable on Cancer and was instrumental in Alphanumeric achieving the Gold Standard Accreditation. Randy’s passion and commitment to empowering future generations is reflected in his appointment as a Wake County Boys & Girls Club Board Member.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2022

"It’s great to be able to say that we are among the leaders in our industry when it comes down not only to execution but also to policy and procedure- two things that set us apart. The accreditation is an honorable nod towards the caliber of people we work with in the pharma and life sciences spaces in North Carolina and globally."
Randy Trice

Alphanumeric

Alphanumeric Systems Inc. started in 1979 as an IT Services company. Over the last decade or so, they’ve transitioned into a life science industry partner that provides a wide variety of expertise and service offerings to enhance and support how their clients engage and connect with patients and healthcare providers. Alphanumeric focuses on three key areas of support, end-to-end contact centers (set-up, support, and engagement), technical support (medical writing, training, education, digital transformation, advisory, and more), and implementation of efficient tools that create customer-centric solutions. Alphanumeric has strategic locations in 11 countries while doing business in 122 countries.
Founding Member

David M. Reese, MD

Executive Vice President and Chief Technology Officer, Amgen
Chairman of the Board, CEO Roundtable on Cancer

Dr. David M. Reese is Amgen's inaugural executive vice president and chief technology officer, responsible for accelerating the use of technology and artificial intelligence across all facets of the company, as well as for the company's Global Medical organization.

Dr. Reese joined Amgen in 2005 and served as executive vice president, Research and Development from 2018 to 2023. During this time, Amgen received approvals around the world for numerous innovative medicines and biosimilars, developed a robust pipeline of potential new medicines, and built a powerful discovery research capability.

Prior to joining Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization.

Dr. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2014 | Gold Standard – China Employer Since 2017

"We are honored to join other leading organizations in the commitment to a healthy workforce as a CEO Cancer Gold Standard accredited corporation. Our mission at Amgen is to serve patients, especially those suffering from serious illness, which makes us acutely aware of the toll cancer can have on patients and their loved ones. In addition to numerous health and wellness programs for our staff members, Amgen supports educational programs and resources ranging from prevention to survivorship for those outside of our company who are affected by cancer."
Robert A. Bradway

Life Sciences Consortium

LSC Task Force Participation

Life Sciences Consortium Chair: Jean-Charles Soria, Senior Vice President of Global Development Oncology

Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium

Data Provider

Since 2015
Communications Support for Project Data Sphere, LLC, 2016-2017

autoRECIST Member

AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Member Since 2010

Peter Sandor

Vice President Oncology, Marketing Strategy

Peter Sandor Vice President, Head of Oncology Therapeutic Area Marketing Strategy. In this role, Peter provides commercial leadership for project’s within the oncology therapeutic area and plays an integral role in the expansion of Astellas’s presence in oncology.

Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2012

Gold Standard Task force Participation

Task Force Member: Tom Mais, Associate Benefits Director

Life Sciences Consortium

LSC Task Force Participation

Task Force Member: Peter Sandor MD, Vice President, Oncology

Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium

Immune-related Adverse Events (irAE) Initiative

Astellas Pharmaceutical, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms – Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us.
Member Since 2004

David Fredrickson

Executive Vice-President, Oncology Business Unit

Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the commercial performance of the AstraZeneca global Oncology portfolio. He has global accountability for marketing, sales, medical affairs and market access in Oncology and plays a critical leadership role in setting the Oncology portfolio and product strategy. Previously, Dave served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain, and strategy, marketing and sales roles in the US. Prior to this, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington DC.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2006

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Andrew Coop. Vice President, US Medical Affairs; David Fredrickson, Executive Vice President, Oncology Business Unit; Michelle Werner MBA, Country President for Nordics & Baltic Markets in Europe; Nevine Zariffa, Vice President

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Pioneering Data Provider

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
Member Since 2021

Dr. Robert J. Brown

CEO and Founder

Dr. Robert Brown is Chief Executive Officer of B&C International (BCI). Throughout his career, Dr. Brown has spent significant time solving problems and cultivating key high level relationships in the United States and on the continents of Africa, Asia and Europe. As BCI’s visionary, he continues to strategically support company platform development, global growth and client engagements.

He also serves as an Ambassador for the CEO Roundtable on Cancer’s Going for Gold initiative, which is focused on improving health equity, education, navigation, and access to care in partnership with academic institutions.

Dr. Brown speaks frequently on race relations, emerging markets and international strategy and was recognized by the Washington Post as a World Class Power Broker. Recently retiring from the boards of the NCAA, Duke Energy, Wachovia Corporation, Wake Forest University Baptist Medical Center and Sonoco Products Company, Dr. Brown is a strong supporter of youth, education and non-violent programs. Dr. Brown currently serves on the boards of High Point University, Boston University, Virginia Union University, National Urban League, Horatio Alger Association and the Richard Nixon Foundation.

Numerous colleges, universities and national organizations have honored Brown. He holds ten honorary doctorate degrees and six national achievement awards. He has also been honored as a recipient of the Horatio Alger Association of Distinguished Americans Award, the Small Business Administration’s Lifetime Achievement Award, the United Way of Greater High Point’s 2002 Alexis de Tocqueville Society Award, The High Point Enterprise 2005 Citizen of the Year Award, the U.S. Department of Commerce’s Minority Business Development Agency’s 2006 Abe Venable Legacy Award for Lifetime Achievement, the U.S. Department of Commerce Minority Business Development Agency’s 2007 National Director’s Legacy Award for Lifetime Achievement and the National Urban League’s 2009 Collins Award.

B&C International

B&C International is a Global Strategy and Business Management Consulting firm headquartered in High Point, North Carolina. During the last 55 years of our existence, the methodologies and tools we use to help our clients efficiently solve problems has evolved, but our core principles remain the same. We are trusted advisors. As the “1st Call” for client concerns, our systematic approach to aligning culture, communication and execution, allows you to gain confidence, clarity and consistency for strategic decision-making.

We understand the value of Human Capital. B&C’s unique people-centered techniques allow you to grow and innovate through overcoming market maturity issues, capitalizing on expansion opportunities, building business models that work for your culture, eliminating departmental silos, maximizing current staffing level productivity, improving the internal interface between baby boomers and millennials, redesigning business models without abandoning who you are, developing a culture of change and accountability, and deepening customer connectivity. We use our influential relationships, resources and staff to assist you in achieving your goals.
Member Since 2004

Robert LaCaze

Executive Vice President, Oncology Strategic Business Unit

Robert joined Bayer as SVP, Head of Oncology TA in October 2015. He has more than 27 years of bio-pharmaceutical experiences most of which has been spent in specialty areas, mainly Oncology. Before joining Bayer, Robert was the SVP, Global Oncology with Bristol-Myers Squibb and co-led the Oncology Disease Strategy team with direct responsible to set the vision, strategy, and execution for the Immuno-Oncology (I-O) Franchise at BMS.

Robert currently serves on the Louisiana Tech College of Business Administration Advisory Board and is a member of AACR and BioNJ. He, his wife and two sons reside in Robbinsville, New Jersey.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2014

Bayer HealthCare is committed to delivering Science For A Better Life by advancing a portfolio of innovative treatments that offer meaningful progress to doctors and patients battling the toughest cancers. The Gold Standard recognition by the CEO Roundtable on Cancer underscores our commitment to fighting cancer, through our Oncology portfolio and ongoing efforts to provide employees with the education and healthcare they need to be as healthy as possible.
Robert LaCaze

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Bhavesh Ashar; Senior Vice President and Head, Oncology; Chandra Ramanathan PHD MBA, Vice President and Head, East Coast Innovation Center; Robert LaCaze, Executive VP, Oncology Strategic Business Uni; Svetlana Kobina MD PhD

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Since 2014

Bayer HealthCare

Bayer HealthCare Pharmaceuticals Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products for diagnosing, preventing, and treating diseases for human health. The company focuses on women’s healthcare, diagnostic imaging, general medicine, hematology/neurology, and oncology products. It provides NEXAVAR, an anticancer medicine used to treat kidney cancer; Stivarga regorafenib tablets for the treatment of patients with metastatic colorectal cancer; Aflibercept (Eylea), an anti-angiogenic therapy for wAMD patients; Xofigo (radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and visceral metastatic diseases; Gadavist, a gadolinium-based contrast agent for pediatric patients; and Dienogest to treat endometriosis in women. Bayer HealthCare Pharmaceuticals Inc. has a strategic alliance with Broad Institute. The company was founded in 1979 and is headquartered in Wayne, New Jersey. Bayer HealthCare Pharmaceuticals Inc. operates as a subsidiary of Bayer AG.
Member Since 2013

Jean-Michel Boers

President and Chief Executive Officer, US Country Managing Director

Mr. Boers joined Boehringer Ingelheim in 1998 in Belgium, and advanced through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries. Mr. Boers came to the U.S. in 2016 as Senior Vice President of the Specialty Care Franchise, and since January 2017, has led the U.S. Human Pharma business. He earned a master’s degree in social and economic history from the University of Nijmegen (Netherlands) and an MBA from the University of Texas.

CEO Cancer Gold Standard™

Gold Standard Employer

"We are truly honored to receive this Gold Standard certification to acknowledge our company-wide efforts to make wellness an integral part of our culture and fight cancer in the workplace. In addition to our efforts at home, we are committed to bringing more health to the oncology community, from our research and development of innovative cancer treatments to resources and initiatives that provide education and support to patients, caregivers and healthcare professionals."
Jean-Michel Boers

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Since its founding in 1885, Boehringer has been committed to the research and development of innovative medicines that transform the lives of people living with cancer.

We take a long-term perspective, embedding sustainability along the entire value chain fostering multi-stakeholder collaboration. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

In 2025 Boehringer Ingelheim achieved HP net sales of 22.9 billion USD. Our significant investment of almost $6.5 billion USD in R&D investments drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we can accelerate innovation and accelerate the breakthroughs that will transform patients’ lives now, and in generations to come.

More information about Boehringer Ingelheim can be found at Boehringer-Ingelheim.com/US or in our mid-year financial report.

About Boehringer Ingelheim in oncology

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Boehringer Ingelheim’s generational commitment to driving scientific innovation is reflected by the company’s robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer’s ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations. Read more at Boehringer-Ingelheim.com/US.
Member Since 2022

Michael F. Mahoney

Chairman and Chief Executive Officer

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health.

Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders.

Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson.

Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business.

Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.
Member Since 2023

James L. Dettore

Founder, Chairman and Chief Executive Officer

James Dettore, senior strategist and founder of Brand Institute in 1993, has been instrumental in advancing BI’s hallmark of innovation and excellence. In 2004, he extended this legacy by establishing Drug Safety Institute (DSI), which has since become a premier company known for providing unparalleled expertise and cutting-edge regulatory services, setting the industry standard.

Mr. Dettore is an alumnus of the Harvard University Graduate School of Business Administration and currently serves on the Executive Committee of the Harvard University New York Chapter Owner & President Management Program (OPM).

In recognition of BI and DSI’s unwavering support of the pharmacy profession and commitment to patient safety, Mr. Dettore was inducted into the Phi Lambda Sigma Pharmacy Leadership Society in 2020. With over three decades of experience in brand management, he has held key positions at renowned organizations, including PepsiCo, J. Walter Thompson, Hilton International Hotels, and Ralph Lauren.

Brand Institute

With gratitude for our remarkable and loyal clientele, Brand Institute has achieved the distinction of being the global leader in pharmaceutical and healthcare-related name and brand identity development. We are honored to have partnered on a portfolio of over 4,600 marketed healthcare brand names and 1,600 USAN/INN (nonproprietary names). This includes over 75 percent of pharmaceutical brand and nonproprietary name approvals globally every year. In the field of oncology alone, we have developed over 850 brand and nonproprietary names, catering to a wide spectrum of clients, from start-up biotech firms to esteemed global pharmaceutical conglomerates. Our success is a direct result of the trust and collaboration of over 1,400 valued clients.

In addition to creating names for pharmaceutical products, Brand Institute has vast experience in developing company names (for new companies as well as rebranding existing ones), clinical trial names, medical device names, OTC product names, technology names, and program names. Our portfolio of services includes name development, trademark searches, market research, visual identity, and regulatory solutions.

Brand Institute’s regulatory services are provided through its wholly owned subsidiary, Drug Safety Institute, which is composed of former regulatory naming officials from global government health agencies, including the U.S. Food and Drug Administration, European Medicines Agency, Health Canada, American Medical Association, and the World Health Organization. These experts offer industry-leading guidance and services related to drug name safety (i.e., preventing medication errors), packaging, and labeling.
Member Since 2004

Giovanni Caforio, MD

Chairman of the Board and Chief Executive Officer

Mr. Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer of Bristol Myers Squibb Australia Pty Ltd. Dr. Caforio serves as Chief Operating Officer at Medarex, Inc. He has responsibility for leading a fully integrated worldwide commercial organization and Medarex-wide functions of Enterprise Services and Global Manufacturing & Supply. He has been the Chief Executive Officer of Bristol Myers Squibb Company since May 5, 2015. He served as Chief Operating Officer Myers Squibb Company since June 9, 2014 and also served as its Chief Commercial Officer and Executive Vice President since November 13, 2013. Dr. Caforio leads the Bristol-Myers Squibb Company’s pharmaceutical business in the U.S. He served as Chief Commercial Officer at Medarex, Inc. Dr. Caforio served as the President of U.S. Pharmaceuticals at Bristol Myers Squibb Company since October 2011. He served as Senior Vice President of U.S. Oncology, Worldwide Pharmaceuticals at Bristol Myers Squibb Company from 2007 to 2009. He served as Senior Vice President of Global Commercialization, Oncology and Immunology at Bristol Myers Squibb from January 2011 to October 2011 and its Senior Vice President of Oncology, Global Commercialization from 2009 to 2010, where he helped re-establish Bristol Myers Squibb as a leader in Oncology, including the launch of YERVOY™, the Bristol Myers Squibb’s innovative immuno-oncology medicine for metastatic melanoma. As a leader, his focus is on developing talented leaders with the diverse experiences and competencies needed for the continued success of the Bristol-Myers Squibb Company. He joined Bristol-Myers Squibb in 2000 as Vice President and General Manager of Italy, in the Worldwide Medicines Group. In 2001, he assumed added responsibility for Greece and Israel, and then all of South East Europe in 2003. Since 2004, he served as Senior Vice President of European Marketing and Brand Commercialization of Bristol Myers Squibb. Since 2007, he served as Senior Vice President of U.S. Oncology of Bristol Myers Squibb. Prior to joining Bristol Myers Squibb, he spent 12 years with Abbott Laboratories in a number of leadership positions. He has been a Director of Bristol Myers Squibb Company since June 9, 2014. He served as a Director of Capital Health System, Inc. until June 17, 2016. Dr. Caforio holds an M.D. from the University of Rome.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2016 | Gold Standard China Employer Since 2018 | Gold Standard Global Employer Since 2019

Receiving the CEO Cancer Gold Standard Accreditation underscores Bristol-Myers Squibb’s commitment to transforming cancer care as well as our unwavering commitment to our patients and our people.
Giovanni Caforio, MD

Gold Standard Task Force Participation

Task Force Member(s): David Shepperly, MD, MHS, FACOEM, Head of Employee Health and Fitness

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Christopher Boerner PhD, President and Head US; Fouad Namouni MD, Oncology Development Head

Bristol Myers Squibb (BMS)

Bristol Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and, rheumatoid arthritis.

At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

The strategy is working. In recent years our total return for shareholders, including dividends, has been among the best in the industry. We outperformed most mega pharma companies, diversified companies and pure biotech companies. Reflecting our long-standing commitment to deliver shareholder value, our company has paid dividends to stockholders for more than 300 consecutive quarters.

We have delivered 12 new medicines to patients in the past 7 years.

Our R&D organization is considered among the most productive in the industry. And the business development strategy of innovative alliances, partnerships and acquisitions further enhances our internal capabilities. Our full array of transactions encompasses many of our key disease areas, along with new areas of focus such as genetically defined diseases and fibrotic diseases.

Pursuing our Mission also means we are working to provide patient access to health care. We are striving to reach that goal through public/private partnerships like SECURE THE FUTURE, our groundbreaking $150 million program to help confront HIV/AIDS in Africa while also developing new, innovative programs to help patients with cancer, hepatitis B and hepatitis C. In addition, through our patient assistance programs, we provide free medications to qualifying patients with financial hardship in the U.S.

Innovation is critical for successfully executing our BioPharma strategy. That innovation is enhanced by a diverse workforce and an inclusive culture. Bristol-Myers Squibb has been recognized year after year as one of the best companies for female executives and working mothers. We’ve also been recognized by the Human Rights Campaign Foundation’s Corporate Equality Index for achieving a perfect score for four consecutive years.

Preservation of our natural resources also represents one of our key commitments. At many of our facilities worldwide, our company is integrating comprehensive energy management, pollution controls and other practices to reduce environmental impacts. Bristol-Myers Squibb is recognized among the leading sustainability-driven companies.

Ultimately, our success as a BioPharma leader is measured by the difference we make in the lives of patients.
Member Since 2020

Ken Keller

President and CEO

Ken Keller is President and CEO of Daiichi Sankyo, Inc. He also leads the U.S. Business and serves as a member of Daiichi Sankyo’s Global Management Committee. Mr. Keller joined Daiichi Sankyo Inc. in 2014.

Through his work with Daiichi Sankyo, and prior to that with Amgen Inc., Mr. Keller has more than 30 years of experience in the pharmaceutical industry. He has led multi-billion dollar businesses in the U.S. and Europe.

Through leadership roles in multiple markets, across cultures and within different healthcare systems, Mr. Keller has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth
Since joining Daiichi Sankyo, Inc., Mr. Keller has shifted the structure of the U.S. business to focus on launching multiple oncology therapeutics in the coming years. He is known for his inclusive leadership approach and his passion for bringing innovative drugs to patients in need.

Mr. Keller is a member of the PhRMA Board of Directors and was previously a board member of the Association of the British Pharmaceutical Industry. He holds a Bachelor of Science degree in Business from Saint John’s University and a Master of Business Administration degree from Loyola Marymount University.

Daiichi-Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. It provides innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, the company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Member Since 2006

Jacob Van Naarden

Executive Vice President, Eli Lilly and Company; President, Loxo at Lilly

Jake Van Naarden serves as executive vice president of Eli Lilly and Company and president of Loxo at Lilly. In this role, Jake oversees all aspects of oncology spanning discovery through commercial. Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the Loxo at Lilly research and development program. In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCorManagement, Aisling Capital, and Goldman Sachs. Jake received his A.B. degree in molecular biology from Princeton University.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2011

"At Lilly, our commitment to making life better goes beyond the medicines we make – it’s at the very heart of our business. We are honored to have been designated a CEO Cancer Gold Standard accredited corporation, which underscores the importance we place on the well-being of our employees. We in Lilly Oncology, continually strive to create an environment of wellness for our employees, one that provides them with the preventive care and education they need to live happy, healthy and productive lives."
Jacob Van Naarden

Gold Standard Task Force Participation

Task Force Member(s): Leslie M Ayres, RN, Manager Corporate Health Services; Charles Williams, Senior Director – Corporate Health Services

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Susan Mahony, PhD, Senior Vice President and President, Lilly Oncology; Anwar M. Hossain, Research Scientist

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Since 2015

Eli Lilly and Company

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

We were founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that meet real needs. More than a century later, we are passionate about building on this precedent in our continued pursuit to make life better for individuals, communities, and the world around us.

Our heritage and our values are the foundation of our promise to unite caring with discovery to make life better for people around the world.

Our mission
We make medicines that help people live longer, healthier, more active lives.

Our values
Integrity, excellence, respect for people

Our vision
We will make a significant contribution to humanity by improving global health in the 21st century.
Member Since 2012

Miguel Fernández Alcalde

President EMD Serono, North America and Head of Global Rare Tumors, Healthcare

Miguel Fernández Alcalde is the President of EMD Serono, leading the North American healthcare business across the U.S. and Canada, as well as leading the Global Rare Tumors Business for the Healthcare organization.

Prior to this role, Miguel served as the Chief Operating Officer and was responsible for driving operational excellence and executing strategies to position EMD Serono for continued success in a dynamic and rapidly changing industry.

Miguel has been with Merck KGaA, Darmstadt, Germany – EMD Serono’s global parent company – since 2014, previously serving in roles such as Vice President, Business Excellence & Innovation and Head of the CEO Office for Healthcare. In this role, he was responsible for ensuring business excellence across all franchises and regions of the healthcare business. Miguel’s responsibilities also included overall governance of the Healthcare CEO Office and contributing to our Healthcare Global Specialty Innovator ambition and Focused Leadership strategy.

With over 20 years of experience in the biotechnology and pharmaceutical sectors, serving as a senior leader in a variety of global and in-market roles, with a special focus on the application of innovative solutions for the improvement of people's health.

Miguel holds a degree in Pharmacy from the University Complutense of Madrid, and a postgraduate degree in Management from the IESE. Miguel is based in our Seaport offices in Boston, MA, and serves as a member of the Healthcare Executive Committee.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2011

Gold Standard Task Force Participation

Task Force Member(s): Ellen Spencer, Manager, Office of the President

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Zhen Su, MD, MBA, Vice President of Medical Oncology

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Data Provider to Project Data Sphere, LLC since 2015

EMD Serono

We are the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.

At EMD Serono, we create, improve and prolong life – every step of the way. We are patient-directed, caring deeply for those with conditions that impact people at all stages of life: infertility, MS, cancer and HIV-associated wasting.

We’re anchored by global roots that run more than 350 years deep, underpinned by a strong core portfolio and compassionate approach. It’s how we’ve built a strong reputation with the healthcare community, patients and their loved ones, and how we are fueling today’s innovation and longer-term aspirations.

Above all, we lead and act as one for patients. We believe better outcomes happen when patients and their loved ones have a say in their treatment regimen. And we know that looking at the patient journey holistically and collaborating across the full healthcare ecosystem will better enable access to medicine and patient results.

By holding ourselves to the high standards we’ve built as specialty innovators, we’re welcoming a future of growth, evolution and medical breakthroughs for our patients, their healthcare teams, and the broader community at large.
Member Since 2015

François Maisonrouge

Senior Managing Director

Francois Maisonrouge is a Senior Managing Director in Evercore Partners’ advisory business with 31 years of relevant experience.

At Evercore, among other transactions, Mr. Maisonrouge was involved in advising Medivation on its sale to Pfizer, AstraZeneca on the sale of its anti-infectives business to Pfizer, Shire on its acquisitions of Baxalta and Dyax, Shire on its defense across from Abbvie, AstraZeneca in its defense across from Pfizer, Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale to Fresenius, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck’s 50% stake in Merial, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer.

Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology.

Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and a Director of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d’Honneur.

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): François Maisonrouge, Senior Managing Director

Evercore Partners LLC

Evercore is a premier independent investment banking advisory firm.
We founded Evercore in 1995, on the premise that clients would be best served by an investment banking firm free of the conflicts of interest inherent to large, multi-product financial institutions. We believed our model would attract the most talented senior finance professionals to our firm. We believed that by maintaining the highest standards of excellence we could create a firm unlike any other in terms of capabilities to advise on highly complex strategic transactions, dedication to our client and our experience and professionalism.

Today, we serve a prominent and diverse set of clients and investors, including leading multinational corporations, large institutional investors and financial sponsors, and high net worth individuals.

Our global expansion continues in order to ensure the worldview and international knowledge base that is now critical to all investors. Today, our offices in North America, Europe, Mexico, Brazil, Hong Kong and Singapore are complemented by strategic alliances with leading firms in China, Japan, India, Korea, Australia and Argentina.

We always strive to enhance our capabilities and expand our global reach thereby providing the highest caliber of various services to our clients.
Member Since 2020

Brian Alexander, MD, MPH

Chief Executive Officer

Dr. Brian Alexander was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer since 2019, and is a practicing radiation oncologist specializing in neuro-oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a Senior Lecturer at Harvard Medical School.

Since joining the company in September 2018 as a Senior Vice President of Clinical Development, Dr. Alexander has played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine’s medical team has expanded its molecular tumor board program to include over 90 leading oncology centers globally, launched a cross-functional genomics and health disparities effort, and has developed hundreds of studies and publications to advance the clinical utility of genomic profiling.

Dr. Alexander was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, and 2021.

Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs, where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.

Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design.

Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2016

Foundation Medicine, Inc.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
Founding Member

Emma Walmsley

Chief Executive Officer

Emma Walmsley is CEO Designate of GSK. She will formally succeed Andrew Witty as GSK CEO when he retires on 31 March 2017. She has been a member of GSK’s Corporate Executive Team since 2011. She joined the GSK Board on 1 January 2017.

Previously, Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis which was created in March 2015. With a turnover of £6bn in 2015, GSK Consumer Healthcare is one of the world’s largest consumer health companies, developing and marketing products in Wellness, Oral Health, Nutrition and Skin Health.

Prior to this Emma was President of GlaxoSmithKline Consumer Healthcare. She joined GSK in 2010, with responsibility for Consumer Healthcare, Europe.

Prior to joining GSK, Emma worked with L’Oreal for 17 years where she held a variety of marketing and general management roles in Paris, London and New York. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China.

Emma was a non-executive director of Diageo plc from 1 January – 21 September 2016.
Emma holds an MA in Classics and Modern Languages from Oxford University.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2017

Gold Standard Task Force Participation

Task Force Member(s): David Siebens, MD, PhD, Medical Services Director – US; Samuel Pelk, Global Health Advisor

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Axel Hoos, MD, PhD, Vice President, Oncology R&D, DPU Head, Immuno-Oncology Combination; Jamey Millar, Senior Vice President, Managed Markets & Government Affairs

GlaxoSmithKline

We are a science-led global healthcare company. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. We have a significant global presence with commercial operations in more than 150 countries, a network of 89 manufacturing sites, and large R&D centres in the UK, USA, Belgium and China
Founding Member

John Crumpler

Co-Founder and General Partner

John co-founded Hatteras in 2000 after an early career in politics and public policy and as founder and CEO of E-Comm, Inc., a software development firm focused on remote and mobile computing. Following E-Comm’s acquisition by XcelleNet (XNET) and later Sterling Commerce (SE), he partnered with Clay Thorp to launch Hatteras, with a focus on supporting innovation in healthcare and life sciences.

At Hatteras, John leads the firm’s investments in healthcare and life science information technology and helps shape the vision and culture that guide the partnership.

Over more than two decades, John and his partners have built a seed- and early-stage venture capital platform with over $900 million under management across seven funds. He has served on the boards of companies acquired by Symyx Technologies, Bioclinica, Press Ganey, HealthStream, NextGen, dMed, Aledade, and Falfurrias Capital Partners. John currently serves on the boards of Huma.ai, Elligo Health Research, Wildflower Health, and BEKhealth, and is a board observer at SafeRide and Gozio. He holds an A.B. from Harvard University.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2016

"The CEO Cancer Gold Standard is the best way I know for any organization to make a real difference in the fight against cancer."
John Crumpler

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm that builds transformational companies in areas of health innovation. We focus on cutting-edge science and teams in biotech, medtech, and healthtech. Many of our companies are based on leading science from academic research institutions. The firm has invested in companies across the United States in most of the major hotspots for health innovation. Given our headquarters location in Research Triangle Park, NC, Hatteras plays a leadership role in building companies in North Carolina and the Southeastern United States, where technology is plentiful but resident venture capital is limited. Core to the mission of Hatteras Venture Partners is a belief that entrepreneurial innovation will create valuable new products that will transform the practice of medicine and create value for our investors. As entrepreneurs, operators, and investors, we are dedicated to the success of our companies and to the men and women who create them. Founded in 2000 and based in Durham, NC, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With seven core funds, the firm has over $900 million under management and has invested in over 100 portfolio companies. Hatteras is an Innovation to Impact sponsor of the Council for Entrepreneurial Development, a member of NCBIO, and an active volunteer in support of North Carolina and Southeast regional biotech activities.
Member Since 2014

Riccardo Braglia, MBA

Helsinn Group Vice Chairman & Group Chief Executive Officer

Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care.

Mr. Braglia is a Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of the Helsinn Investment Fund, Luxembourg. Mr. Braglia serves as a Board Member of two portfolio companies of the Helsinn Investment Fund, QuantumDx Group Limited, UK and GreenBone Ortho S.R.L., Italy. He is also Co-founder and Board Member of Lyfebulb, USA, and a Board Member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health Elements.com, all US companies. Mr. Braglia is a member of the Board of the Conquer Cancer Foundation, USA. Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures.

Riccardo Braglia holds a degree in Business Economics with a specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2015 | Global Gold Standard Employer Since 2015

"Helsinn’s mission is to bring respect, integrity, and quality to our products, services and all that we do to improve health and quality of life in every person affected by cancer. We are honored to be accredited CEO Cancer Gold Standard which means quality of life for our employees and is an additional step forward to reach our mission."
Riccardo Braglia, MBA

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Sergio Cantoreggi, PhD, Chief Scientific Officer & Global Head of R&D

Helsinn Healthcare SA

The Helsinn Group is one of the world’s leading supportive cancer care companies. Our business model is built on forging lasting alliances with worldwide partners who share our vision. Through a mix of integrated early and late stage licensing programs and our own development, we have developed a comprehensive portfolio of effective pharmaceuticals and specialist therapies that are sold in over 90 countries, and a late stage pipeline of future cancer therapies which will meet unmet medical needs in the treatment of cancer.
Founding Member

Joaquin Duato

Vice Chairman of the Executive Committee of Johnson & Johnson

Joaquin Duato is a globally experienced, values-driven health care business leader and currently Vice Chairman of the Executive Committee of Johnson & Johnson, the world’s premier health care company. Joaquin is responsible for the Company’s Pharmaceuticals and Consumer sectors, along with Supply Chain, Technology and the Health & Wellness groups. He is a respected industry leader and past Chairman of the Pharmaceutical Research and Manufacturers of America.

As a member of the company for more than 30 years, Joaquin played an instrumental role in leading the turnaround of Johnson & Johnson’s Pharmaceuticals sector. Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment to his role as Executive Vice President and Worldwide Chairman, Pharmaceuticals in 2011. During that time, the sector grew into what is today the third-largest innovative pharmaceutical company globally.

More recently in his role as Vice Chairman, Joaquin provides strategic direction for the sectors and functions he oversees. He helped guide the transformation of Johnson & Johnson’s Consumer Health sector, under which the business has renewed its focus on Self-Care and Skin Health brands that are rooted in science and endorsed by professionals. Additionally, Joaquin is championing the use of new technologies across Johnson & Johnson so the company can continue leading in a digital world, with a focus on the application of Data Science, Intelligent Automation and other digital technologies.

As a dual citizen of Spain and the United States with extensive experience living and working on-the-ground on multiple continents, Joaquin brings a unique international perspective to his work. His global experience has given him an appreciation for the value of diversity of thought and opinions, which he brings to bear externally as a UNICEF USA Board Member, Tsinghua University School of Pharmaceutical Sciences Advisory Board Member and Hess Corporation Board Member, and internally as the Executive Sponsor of the African Ancestry Leadership Council. His commitment to nurturing a culture of diversity and inclusion was recognized by the Healthcare Businesswomen’s Association (HBA) when he was named 2017 Honorable Mentor. Joaquin has an undergraduate degree in economics and business, a Master of Business Administration degree from ESADE Business School in Barcelona and a Master of International Management degree from Thunderbird in Phoenix, Arizona. Follow Joaquin on Twitter at @joaquinduato.

CEO Cancer Gold Standard™

Gold Standard Employer

Gold Standard Employer Since 2006 | Global Gold Standard Employer Since 2013

It’s an honor to earn the Gold Standard accreditation for the 10th consecutive year, and it’s a recognition that I attribute to our strong culture of health. Our employee wellness programs at Johnson & Johnson have, undoubtedly, led to a healthier and more productive, engaged and satisfied workforce, which reaffirms our belief that an investment in our employees’ health is an investment in our company’s health. – Alex Gorsky
Joaquin Duato

Gold Standard Task Force Participation

Task Force Member(s): Marcelo Targino, MD, MPH, FACOEM, FACP, Chief Health Officer & Corporate Medical Director; Jennifer Bruno, Vice President, Global Health Services

Global Gold Standard Task Force Participation

Member Global Gold Standard Subcommittee: Marcelo C. Targino, MD, MPH, FACOEM, FACP, Chief Health Officer & Corporate Medical Director

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Wayne Rackoff, VP Clinical Oncology; William Hait, MD, PhD, Global Therapeutic Area Head

Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium

Data Provider

Pioneering Data Provider

autoRECIST Program Member

Johnson & Johnson

Caring for the world, one person at a time… inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Our Family of Companies comprises:
•The world’s sixth-largest consumer health company
•The world’s most comprehensive medical devices business
•The world’s sixth-largest biologics company
•And the world’s fifth-largest pharmaceuticals company

We have more than 265 operating companies in more than 60 countries employing approximately 126,500 people. Our worldwide headquarters is in New Brunswick, New Jersey, USA.
Member Since 2006

Peter W.T. Pisters, MD

President

Officially named president in September after being unanimously selected as the sole finalist by the UT System Board of Regents, Peter WT Pisters, MD previously served MD Anderson in faculty and leadership roles for more than 20 years. Most recently, he was president and chief executive officer of the University Health Network (UHN) in Toronto, Canada.

Pisters oversaw more than 14,000 employees and a $400 million research enterprise at UHN, Canada’s largest hospital-based research program, beginning in January 2015. Prior to his appointment at UHN, he was vice president for MD Anderson’s regional care system, comprising multiple Houston-area locations.

Pisters initially joined MD Anderson’s faculty in 1994 as assistant professor of Surgery, rising to full professor with tenure in 2004. His specialties are sarcoma and gastrointestinal cancer, and he remains a board-certified surgeon. He also holds a master’s degree in health care management from Harvard University.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2007

Gold Standard Task Force Participation

Task Force Member(s): Bret J. Belfer, Director, Employee Wellness and Recognition

Life Sciences Consortium

LSC Task Force Participation

Task Force Member(s): Donald A. Berry, PhD, Professor, Department of Bio-statistics

The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention.

Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History.
Core Values

Caring: By our words and actions, we create a caring environment for everyone.
- We are sensitive to the concerns of our patients and our co-workers.
- We are respectful and courteous to each other at all times.
- We promote and reward teamwork and inclusiveness.
Integrity: We work together to merit the trust of our colleagues and those we serve.
- We hold ourselves, and each other, accountable for practicing our values.
- We communicate frequently, honestly and openly.
- By our actions, we create an environment of trust.
Discovery: We embrace creativity and seek new knowledge.
- We help each other to identify and solve problems.
- We seek personal growth and enable others to do so.
- We encourage learning, creativity and new ideas.
Member Since 2025

Michelle Longmire, MD

CEO & Co-Founder

As the co-founder and Chief Executive Officer of Medable, Dr. Michelle Longmire is mission-driven to accelerate the development of new therapies for disease. A Stanford-trained physician-scientist, Dr. Longmire witnessed firsthand the critical barriers to drug development – including the time and costs associated with clinical trial participation. She founded Medable to pioneer a new category of clinical trial technologies that remove traditional roadblocks to participation and radically accelerate the research process. Medable is now the industry leader in decentralized and direct-to-patient research, with the ability to serve patients in over 120 languages, 60 countries, and across all therapeutic areas. In addition to having raised over $500M in venture capital and driving Medable to an industry-leading position, Dr. Longmire has received recognition as a leading innovator and businesswoman, including being named as one of the 100 most creative people in business by Fast Company.

Medable

Medable is on a mission to get effective therapies to people faster. Its AI-powered clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc.5000 in 2024.
Member Since 2020

Elcin Barker Ergun

Group CEO and Member of the Board of Directors Menarini Group

Elcin Barker Ergun joined Menarini Group in 2019 as Group CEO and Member of the Board of Directors after an expansive international career in the US, Europe, and Emerging Markets. She has worked in Global, Regional, and Local Leadership roles in the Pharma Industry for more than 25 years in Innovation, Commercial, and Finance Leadership.

Since her appointment as Group CEO, Ergun has spearheaded Menarini’s entry into the US pharma market and into oncology through the acquisition of Stemline Therapeutics accelerating the company’s growth and innovation power.

Before joining Menarini, she worked at Merck for 4 years as Executive Vice President, Head of New Businesses, driving the external innovation R&D strategy based in Boston. Prior to that, she worked as Executive Vice President, Chief Commercial Officer of Merck Serono in the company’s headquarters in Germany after leading the MEA, Russia, CIS as Senior Vice President of the Region.

Ergun entered the Pharma Industry with GlaxoSmithKline as subsidiary CFO. In her earlier career, Ergun worked in the UK for Honeywell and in the Netherlands for ITT Corporation in IT Management, where she started as a software engineer. Ergun has a BSc degree in Computer Engineering from METU and an MBA from INSEAD.

Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

Stemline Therapeutics Inc.

Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.
Founding Member

Robert M. Davis

Chief Executive Officer and President

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2018

Merck is at the forefront of cancer research, with inventions that are helping to transform prevention and treatment of the disease. However, our commitment to tackling cancer extends beyond our scientific research. At Merck, our employees are our most critical resource, which is why we’re pleased to be recognized with The Gold Standard. When our employees feel their best, they can be and do their best, which is crucial to helping us achieve our mission of improving and saving lives.
Robert M. Davis

Gold Standard Task Force Participation

Task Force Member(s): Virgina Peddicord, Director

Life Sciences Consortium

LSC Task Force Participation

Task Force Leadership: Kald Abdallah, MD, PhD, AVP, US Oncology Global Medical Affairs & Leader, Oncology Global Medical Affairs
Task Force Member(s): Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical Officer; Eric Rudin, MD, Vice President and Therapeutic Area Head

autoRECIST Program Member

Merck & Co., Inc.

We are a global healthcare company with a 125-year history of working to make a difference. To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
FOUNDING MEMBER

Robert M. Davis

Chief executive officer and president

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

CEO Cancer Gold Standard™

Gold Standard Employer

Since 2018

Merck is at the forefront of cancer research, with inventions that are helping to transform prevention and treatment of the disease. However, our commitment to tackling cancer extends beyond our scientific research. At Merck, our employees are our most critical resource, which is why we’re pleased to be recognized with The Gold Standard. When our employees feel their best, they can be and do their best, which is crucial to helping us achieve our mission of improving and saving lives.
Robert M. Davis

Gold Standard Task Force Participation

Task Force Member(s): Virgina Peddicord, Director

Life Sciences Consortium

LSC Task Force Participation

Task Force Leadership: Kald Abdallah, MD, PhD, AVP, US Oncology Global Medical Affairs & Leader, Oncology Global Medical Affairs
Task Force Member(s): Roy D. Baynes, MD, PhD, Senior Vice President & Head of Global Clinical Development, Chief Medical Officer; Eric Rudin, MD, Vice President and Therapeutic Area Head

autoRECIST Program Member

Merck & Co., Inc.

We are a global healthcare company with a 125-year history of working to make a difference. To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

1 | 2